C
eliac disease, also known as sprue, is a gluten-sensitive enteropathy elicited by an autoimmune response to the ingestion of wheat, rye, and barley 1 and possibly oats. 2 The treatment is lifelong total abstinence from gluten, 1 the alcoholsoluble peptides responsible for triggering the hypersensitivity. Gluten in all forms and amounts must be excluded from food, 1 drugs, 1, 3 and nutritional products 3 ingested by people with celiac disease.
Celiac disease is more common than most health care providers realize. In several European countries, the prevalence is approximately 1 in 300. [4] [5] [6] [7] Preliminary studies in the United States indicate a similar prevalence. 7 Classic symptoms include diarrhea, abdominal distention, weight loss, and asthenia; nongastrointestinal symptoms also often occur. 6, 8 Consequences of untreated celiac disease can include malnutrition, osteoporosis, 9 ,10 malignancy, 4, 5, 11, 12 anemia, and infertility. 4, 5 Total permanent exclusion of gluten allows rejuvenation of the small bowel and reso-lution of symptoms, and complications are prevented or curtailed. 4, 5, [9] [10] [11] [12] [13] Optimal care of the celiac disease patient requires that the pharmacist and other members of the health care team have accurate information about the gluten content of pharmaceutical and nutritional products. The objective of this study was to identify pharmaceutical companies with an established policy of producing only gluten-free products and to identify specific gluten-free and gluten-containing products produced by companies without such a policy.
Methods. We designed a six-item survey to update and extend the findings on gluten-free pharmaceutical and nutritional products previously reported by Olson and Gallo 14 and Pence and Garrison. 15 In March and April 1998 we mailed 172 surveys to pharmaceutical companies listed in the 1998 Physicians' Desk Reference 16 and the 1998 generics supplement to Pharmacy Times. 17 Follow-up telephone calls were made to companies that did not respond within a reasonable period. Responses were collected from March 1998 to July 1999.
The first survey item asked if the company had a policy of producing gluten-free products. If the answer was affirmative, the respondent was directed to the second item, which asked if the company guaranteed the gluten free status of its products. If the company did not have a policy, the respondent was directed to item 3, which asked the respondent to identify products that were known to be gluten free. Item 4 asked the respondent to list any company products known to contain gluten or whose gluten status was unknown. Item 5 asked for a listing of any excipients commonly used in the company's products that were potential sources of gluten. The sixth item allowed the respondent to offer explanations of or disclaimers to the information.
Results. Completed surveys were
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in their products were corn or potato based, they could not exclude the possibility that minute amounts of gluten contaminants from other raw materials at the same locations were present in their inactive ingredients. Commonly, respondents warned that, although their products were gluten free at the time of the survey, their suppliers of raw materials and inactive ingredients could change without notice and that this might affect the gluten status of products. They stressed that information about received from 38 companies after the initial mailing. Another 26 companies responded in the form of a letter rather than with a completed survey. These letters partially or completely responded to the survey questions. Follow-up telephone calls netted 14 additional written responses and 22 oral responses. Five companies responded by returning an uncompleted survey; each stated that the information being sought was not applicable because the company did not manufacture any product (i.e., the company was a distributor, repackager, etc.). The remainder failed to return the survey or to respond to the telephone call. One survey was returned initially as "addressee unknown." Five respondents stated that their company had an established policy of producing gluten-free products, and five stated that they guaranteed the gluten-free status (Table 1) . Table 1 also identifies responding companies that did not have a policy or guarantee the gluten-free status of their products but stated that they believed all their products were gluten free. Another group of respondents did not refer to their products as gluten free but stated that they added no ingredients derived from wheat, oats, rye, barley, or spelt (Table 2 ). They generally claimed that this information was offered so that the celiac disease patient and his or her physician could make a decision about the appropriateness of a product for a patient. In answering survey items 3 and 4, respondents named the specific products that were known to be gluten free (Appendix A) and those known to contain gluten or whose gluten status was unknown (Appendix B). Only one respondent completed item 5, the question that asked for a list of gluten-containing ingredients commonly used in the company's products.
Several disclaimers or explanations were received from respondents who had neither a policy nor a guarantee regarding the gluten status of their products. Most commonly, these respondents explained that, although they believed that their products were devoid of gluten, they neither certified the gluten-free status nor tested for gluten in the final products. Several companies also explained that they could not guarantee the gluten-free status of finished products because they were unable to obtain guarantees of gluten-free status from the suppliers of raw materials. Other respondents indicated that, although the starch derivatives Table 1 .
Companies Indicating Their Products Are Gluten Free a
a Unless otherwise indicated, companies indicated a belief but had no policy or guarantee that their products were gluten free. For such companies, the gluten-free status of any product may change in the future.
b Has a policy of producing gluten-free products. gluten content was only as current as the date of correspondence. Lastly, many respondents stated that they were not able to provide a list of gluten-free or gluten-containing products but were able and willing to investigate the gluten content of an individual product in a specific lot for an inquiring health care provider or patient.
Discussion. The information obtained from this survey, although somewhat dated, highlights the challenges in obtaining gluten-free drug and nutritional products. Few companies reported definitively that their products were gluten free. Raw materials obtained from outside sources were the primary reason for this ambiguity.
Gluten, when present in drug and nutritional products, is a component of inactive ingredients added during manufacturing. Inactive ingredients derived from whole grains, grain flour, or grain starch are the most common sources of gluten. Excipients, such as unspecified starch [18] [19] [20] or pregelatinized starch, 18 ,20 dusting powder, flour, and gluten, 3,21 may be derived from wheat. These inactive ingredients have the highest potential to be sources of gluten in drug and nutritional products. Dextri-Maltose and caramel coloring may be sources of gluten when barley malt is used in manufacturing. 20, 22 Other starch derivatives, such as sodium starch glycolate, 20 ,23 dextrin, 24 and maltodextrin, 20 are processed almost exclusively from potato starch or cornstarch but may rarely be derived from other starches. The botanical source of each of these ingredients must be determined before the product can be considered safe for the celiac disease patient. Procuring gluten-free products is facilitated when a pharmaceutical company has an established policy of producing only gluten-free products. In such a case, much of the uncertainty about the appropriateness of a product for the celiac disease patient is removed. Only five of the companies surveyed had such a policy, however. Further complicating the picture is that information is only as current as the date on which it was communicated. Consequently, the patient, the pharmacist, or the physician must contact a manufacturer periodically to be sure that a given product's status has not changed. It is best to refer to the lot number of the product whenever possible.
The claim "new formulation," "new product appearance," or "new manufacturer" on a product label is an important indicator of a potential change in the product's gluten status. Either active ingredients or excipients may have changed. Such claims should alert the health care provider or the patient to contact the manufacturer to determine if the change affected the product's gluten status.
For patients with celiac disease, any medication that enters the gastrointestinal tract, whether it is orally or rectally administered, must be gluten free. The risk of inadvertent gluten ingestion comes not only from limited knowledge about potential gluten-containing excipients but also from failure to disclose excipient sources in package labeling. In our survey, a significant number of respondents were not aware of excipients other than wheat starch that may contain gluten. Currently, a few prescription medications are actually labeled "gluten free" (e.g., prednisone and dexamethasone tablets manufactured by Roxane Laboratories). If this information were included on all gluten-free medications, it would greatly help those with celiac disease avoid gluten intake. A reliable means of identifying and obtaining gluten-free medications and nutritional products is essential to the health of these persons.
Conclusion. Only 5 of 100 pharmaceutical companies that responded to a survey reported having a policy of producing gluten-free products. Many companies believed their products to be gluten free but could not guarantee it. 
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